New drug tested for rare Cancer-Related flushing and diarrhea
NCT ID NCT05361668
Summary
This study tested a drug called paltusotine in people with carcinoid syndrome, a condition caused by certain rare tumors that leads to severe flushing and diarrhea. Thirty-six participants took either a 40 mg or 80 mg dose for 8 weeks, with the option to continue for up to 28 months. The main goals were to check the drug's safety, how it moves through the body, and whether it helped control symptoms.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOID SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Crinetics Study Site
Los Angeles, California, 90048, United States
-
Crinetics Study Site
Los Angeles, California, 90095, United States
-
Crinetics Study Site
Newport Beach, California, 92663, United States
-
Crinetics Study Site
Stanford, California, 94305, United States
-
Crinetics Study Site
Miami, Florida, 33136, United States
-
Crinetics Study Site
Iowa City, Iowa, 52242, United States
-
Crinetics Study Site
Lexington, Kentucky, 40506, United States
-
Crinetics Study Site
New Orleans, Louisiana, 70112, United States
-
Crinetics Study Site
Boston, Massachusetts, 02118, United States
-
Crinetics Study Site
Rochester, Minnesota, 55905, United States
-
Crinetics Study Site
New York, New York, 10029, United States
-
Crinetics Study Site
Stony Brook, New York, 11794, United States
-
Crinetics Study Site
Cleveland, Ohio, 44106, United States
-
Crinetics Study Site
Columbus, Ohio, 43210, United States
-
Crinetics Study Site
Houston, Texas, 77030, United States
-
Crinetics Study Site
CABA, Buenos Aires, C1180 AAX, Argentina
-
Crinetics Study Site
CABA, Buenos Aires, C1264AAA, Argentina
-
Crinetics Study Site
CABA, Buenos Aires, C1426ANZ, Argentina
-
Crinetics Study Site
CABA, C1017AAS, Argentina
-
Crinetics Study Site
CABA, C1425BGH, Argentina
-
Crinetics Study Site
Fortaleza, Ceará, 60430-275, Brazil
-
Crinetics Study Site
Rio de Janeiro, Rio de Janeiro, 20231-092, Brazil
-
Crinetics Study Site
Rio de Janeiro, Rio de Janeiro, 22281-100, Brazil
-
Crinetics Study Site
Criciúma, Santa Catarina, 88811508, Brazil
-
Crinetics Study Site
São Paulo, São Paulo, 01509-010, Brazil
-
Crinetics Study Site
Rio de Janeiro, 22061-080, Brazil
-
Crinetics Study Site
Toronto, M4N 3M5, Canada
-
Crinetics Study Site
Mexico City, Cuauhtemoc, 06100, Mexico
-
Crinetics Study Site
Querétaro City, Querétaro, 76000, Mexico
-
Crinetics Study Site
Querétaro City, Querétaro, 76070, Mexico
-
Crinetics Study Site
Katowice, 40-514, Poland
-
Crinetics Study Site
Warsaw, 02-351, Poland
-
Crinetics Study Site
Wroclaw, 53-413, Poland
-
Crinetics Study Site Peru #1
Lima, 15036, Peru
-
Crinetics Study Site Peru #2
Lima, 15036, Peru
Conditions
Explore the condition pages connected to this study.